title: [The ability to use meldonium as adaptogen in winter in patients with cardiovascular disease].
abstract: Given that the effects of frost can play the role of independent stress factor influencing the course of cardiovascular disease (CVD), it is reasonable to supplementation of drugs that increase the body's resistance to cold stress. Aim: To evaluate the possibility of using meldonium to prevent unwanted seasonal changes in CVD patients in the winter. The study included 49 patients with CVD aged 38-75 years. Patients were randomized into 2 groups: active management (M), in which in addition to the basic therapy received during the winter 3 months meldonium 1000 mg/day, and a control (K). We measured office blood pressure, heart rate, blood chemistry, determination of glycosylation end products (DGP). Filled with a visual analogue scale (VAS) to assess the quality of life (QOL). During frost marked increase in blood glucose (p = 0.02) in group K, persisting throughout the winter, and an increase in tissue DGP in March (p = 0.002). In group M glucose and DGP not significantly raised. In group M at the peak of cold showed a reduction in cholesterol levels. Admission meldonium associated with improved quality of life, in the dynamics of the group K was negative [Δ +10.0 VAS scores in group M versus -7.5 points in the group K in the cold (p = 0.04) and Δ +10,0 points vs -5.0 points, respectively, in March 2014 (p = 0.055)]. Adding to the basic treatment of patients with CVD meldonium in a dose of 1000 mg/day in winter, accompanied by improved quality of life, as well as let negative changes in carbohydrate metabolism.
authors: M D
authors: MD
authors: Smirnova
authors: O N
authors: ON
authors: Svirida
authors: F T
authors: FT
authors: Ageev
authors: T V
authors: TV
authors: Forfanova
authors: M V
authors: MV
authors: Vitsenia
authors: G V
authors: GV
authors: Mikhaĭlov
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000368:Aged; D050260:Carbohydrate Metabolism / Q000187:drug effects; D002317:Cardiovascular Agents / Q000145:classification / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D003080:Cold Temperature / Q000009:adverse effects*; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage*; D008875:Middle Aged; D012621:Seasons; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate